Methods of treating mixed dyslipidemia

Abstract

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

I/We claim: 
     
         1 . A method of treating or preventing a cardiovascular disease in a subject in need thereof, the method comprising administering eicosapentaenoic acid (EPA) and a statin to the subject, wherein the EPA and the statin are present in a capsule, the EPA is present in an amount of at least about 95%, by weight, of all fatty acids, and the EPA is administered to the subject in an amount sufficient to provide a dose of about 2,500 mg to about 10,000 mg of the EPA per day. 
     
     
         2 . The method of  claim 1 , wherein the EPA is ethyl-EPA. 
     
     
         3 . The method of  claim 1 , wherein the EPA is administered to the subject in an amount sufficient to provide a dose of about 4,000 mg of the EPA per day. 
     
     
         4 . The method of  claim 1 , wherein the statin is at least one selected from the group consisting of lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin, and simvastatin. 
     
     
         5 . The method of  claim 1 , wherein the statin is atorvastatin. 
     
     
         6 . The method of  claim 1 , wherein the cardiovascular disease is myocardial infarction, stroke, or both. 
     
     
         7 . The method of  claim 1 , wherein the subject has a baseline LDL-C level of at least 100 mg/dl, a baseline non-HDL-C level of at least 130 mg/dl, and/or a baseline triglyceride level of at least 250 mg/dl. 
     
     
         8 . The method of  claim 1 , wherein the statin and the EPA are administered for a period of time to reduce an Apo-B level and a baseline non-HDL-C level in the subject. 
     
     
         9 . The method of  claim 1 , wherein the statin and the EPA are administered for a period of time to reduce an Apo-B level in the subject without increasing the baseline LDL-C level in the subject. 
     
     
         10 . The method of  claim 7 , comprising administering the statin and the EPA for a period of time to reduce an Apo-B level in the subject compared to a control subject who has a baseline triglyceride level of at least about 250 mg/dl and has received the statin but not the EPA. 
     
     
         11 . The method of  claim 1 , wherein the statin and the EPA are administered to the subject for a period of time of at least about 2 years. 
     
     
         12 . The method of  claim 3 , wherein the capsule is substantially free of docosahexaenoic acid (DHA). 
     
     
         13 . The method of  claim 12 , wherein the EPA is present in four 1 g capsules. 
     
     
         14 . The method of  claim 12 , wherein the statin is rosuvastatin and 5 mg of the rosuvastatin is present in at least one of the four capsules. 
     
     
         15 . The method of  claim 12 , wherein the statin is rosuvastatin and 10 mg of the rosuvastatin is present in at least one of the four capsules. 
     
     
         16 . The method of  claim 12 , wherein the statin is rosuvastatin and 20 mg of the rosuvastatin is present in at least one of the four capsules. 
     
     
         17 . The method of  claim 12 , wherein the statin is rosuvastatin and 40 mg of the rosuvastatin is present in at least one of the four capsules.